Eli Lilly to acquire Dermira for $1.1 billion
16-01-2020
Eli Lilly licenses AI tech for preclinical development
06-06-2019
Jonathan Weiss / Shutterstock.com
American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Centrexion Therapeutics, chronic pain, non-opioid, CNTX-0290, patent licensing, exclusive, SSRT4
